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Prostate-specific membrane antigen (PSMA) overexpression is observed in the 
neovasculature of solid tumors, but not in the vasculature of normal tissues. Increased 
PSMA expression is positively associated with tumor stage and grade, although its 
function in cancer remains unclear. Mouse double minute 2 (MDM2) is a negative 
regulator of the p53 tumor suppressor and is reported to regulate VEGF expression 
and angiogenesis. Both proteins have been considered as biomarkers and therapeutic 
targets for advanced solid tumors. Our work and a recent microarray-based gene 
profiling study suggest there could be signaling interplay between MDM2 and PSMA. 
We herein review the mechanisms underlining the outgrowth of tumors associated 
with PSMA and MDM2, their potential interaction and how this may be applied to 
anticancer therapeutics.
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Tumorigenesis & clinical relevance of 
MDM2
The transformation potential of Mouse dou-
ble minute 2 (MDM2) was discovered when it 
was revealed that MDM2 can bind to the p53 
tumor suppressor and thus inhibit its transac-
tivation. Since then, in vivo experiments have 
provided compelling evidence toward the 
importance of the MDM2/p53 interaction [1].
The p53 protein transcriptionally activates 
many genes, including the mdm2 gene [2]. 
Therefore, p53 is regulated at protein level 
by MDM2, but once active, p53 triggers the 
transcription of the mdm2 gene, locking the 
proteins into a tight negative feedback loop, 
vital for cell survival [3].
Apart from its involvement in p53-depen-
dent activities, MDM2 also plays a role in 
p53-independent cellular functions which 
contribute to tumorigenesis [4]. It is now 
known that MDM2 binds and regulates 
many proteins independent of p53, includ-
ing proteins involved in DNA repair, DNA 
replication, cell–cycle control and apoptosis. 
These pathways work in chorus to preserve 
the integrity of genetic information and it 
has been suggested that MDM2 may act as 
a central node in the regulation of genome 
stability and, hence, transformation [5].
MDM2 is overexpressed due to amplifica-
tion in around 10% of all human cancers, 
and overexpression via other mechanisms also 
occurs in many human malignancies [6]. This 
means that development of a therapy involv-
ing the inhibition of MDM2 could be used 
to treat many different patients with various 
cancer types. Therefore, MDM2 is a major 
target for drug companies in the  development 
of therapies for cancer patients.
MDM2 as a therapeutic target
The main focus of most therapeutics targeted 
at MDM2 is to decrease the level of MDM2 
protein in cells and therefore allow the reac-
tivation of p53. There are several approaches 
undertaken to accomplish this: reducing 
MDM2 levels in cancer cells, inhibiting the 
E3 ubiquitin ligase complex of MDM2 or the 
disrupting the interaction between p53 and 
MDM2 [7].
A basic strategy to decreasing MDM2 
protein expression is to specifically target 
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the gene using small interfering RNA (siRNA), short 
hairpin RNA (shRNA) or miRNA approaches [8]. The 
downregulation of MDM2 using antisense oligonucle-
otides has led to the stabilization and activation of the 
p53 pathway in cancer cells growing in culture and in 
tumor xenograft mice. Interestingly, mutant p53 cells 
have responded equally as well as those harboring wild-
type p53. This result supports the notion that MDM2 
has other p53-independent activities involved in its 
contribution to tumor growth and progression [9].
Another way to reactivate p53 activity is to inhibit 
the ubiquitin ligase activity of MDM2 [10]. Recently, 
small-molecule inhibitors have been discovered which 
specifically target the E3 ligase activity of MDM2. 
Numerous compounds from this group of inhibitors 
have been shown to inhibit in vitro p53 ubiquitina-
tion [11]. Studies using cancer cells reported that these 
molecules activate p53 signaling and thus induced 
apoptosis. However, these compounds have shown low 
potency and selectivity, with more optimization being 
vital before assessment of the therapy’s potential [11,12].
Small molecule inhibitors of the MDM2-p53 inter-
action have been identified, with the logic that disrup-
tion of binding will lead to a degradation of p53. In 
the past decade, much effort has been invested in this 
approach, with a recent yield of the first potent and 
selective pharmacological activators of wild-type p53. 
A few of these small molecules do represent viable leads 
for the development of therapeutic agents. The first of 
these MDM2 antagonists, the nutlins, were identified 
from a class of compounds named cis-imidazoles [13,14]. 
The nutlins displace p53 from MDM2 in vitro and 
crystal structures have shown that they bind to the p53 
pocket of MDM2 in a way which remarkably mimics 
the molecular interactions between the two proteins. 
Proliferating cancer cells have been shown to be effec-
tively blocked in the G1 and G2 phases and undergo 
apoptosis following treatment with these inhibi-
tors [13]. The nutlins were the first molecules to prove 
that activation of wild-type p53 using pharmacological 
inhibitors of the MDM2-p53 interaction was a feasible 
therapeutic concept. As predicted by the molecular 
mechanism, it seems that only cells with wild-type 
p53 are sensitive to these compounds, so p53 status of 
tumors would need to be determined before any thera-
peutic approach is undertaken. In vitro and in vivo 
studies conducted using the nutlins have verified their 
antitumor effect [15].
Recently, there has been an influx of small molecule 
MDM2 inhibitors undergoing clinical trials, with 
seven currently in Phase I, all of which target the inter-
action between MDM2 and p53 [16]. The first of these, 
AM 232 was discovered through studies into AM 8553, 
a compound produced using de novo design strategy 
based on the structure of MDM2. AM 232 targets a 
shallow cleft on the surface of MDM2; has been found 
to be potent and selective; and has shown notable 
antitumoral activity in vivo [17,18]. Roche currently 
have two compounds in trials, R05045337 (RG7112) 
and R05503781 (RG7388), with R05045337 being 
based on the original Nutlin family of inhibitors [19]. 
R05503781 is the second generation of R05045337, 
with superior potency and selectivity [20]. Novartis have 
developed a drug named CGM097 which has been 
optimized and moved to clinical trials, with analogs 
currently being developed and their efficacy assessed in 
vivo [21]. A fifth inhibitor, named DS-3032b was devel-
oped by Daiichi Sankyo following a miniaturized ther-
mal denaturation assay used to screen chemical librar-
ies, leading to a unique series of benzodiazepinedione 
antagonists of the MDM2-p53 interaction being dis-
covered [22]. SAR4058383 was developed by the Uni-
versity of Michigan and Sanofi, with promising early 
studies showing that a single optimized oral dose of 
the compounds leading to complete tumor regression 
in the SJSA-1 cell line model [23]. Finally, MK-8242 
was developed by Merck Sharp & Dohme Corp and a 
clinical trial of patients with solid tumors was recently 
completed [16].
It is well known that, following DNA damage, p53 
is activated and this leads to arrest of the cell cycle and 
apoptosis in sensitive tissues [24]. Therefore, a main 
concern of using therapeutics to activate p53 is the 
effect of this act in normal tissues. Mice with MDM2 
reduced to around 30% of its normal level show 
increased p53 in all tissues tested. Apart from slight 
disturbances in hematopoiesis and an increase in apop-
tosis in the small intestine, these mice developed nor-
mally [12,25]. Further, nude mice can tolerate nutlin-3 
for 3 weeks at doses that cause inhibition and regres-
sion of tumors [15]. It seems that these studies suggest 
that perhaps activation of p53 through MDM2 inhibi-
tion may be a promising therapeutic option and can be 
well tolerated in vivo [12].
Although use of these inhibitors can be extremely 
useful for cancer therapeutic development, their effec-
tiveness depends on multiple factors. First, as already 
mentioned, the therapeutic effect of p53 activation 
could be abolished through the potential cell cycle 
arrest or cell death caused by p53 activation. Second, 
MDM2 is not the only regulator of p53 in cells, so 
other interactors may hinder the cellular response to 
MDM2 antagonists. For example, MDMX, another 
p53-binding protein, cannot be displaced by nutlin-3, 
so the effectiveness of nutlins can be compromised in 
tumor cells which overexpress MDMX [12].
Therefore, although MDM2 represents a useful and 
potent target for inhibitors in the impedance of can-
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cer progression, an ideal therapeutic has not yet been 
identified. However, with our new understanding of 
the functions of p53-dependent and -independent 
MDM2 and accelerating speed of drug development, 
it is possible that an MDM2-targeted therapy could be 
effectively applied to halt tumor outgrowth in patients 
(clinical trials of MDM2-targeted  therapeutics 
 summarized in Table 1 [26]).
Clinical relevance of PSMA
Prostate-specific membrane antigen (PSMA) has only 
a few sites of expression in normal tissues: the prostate 
epithelium, the kidney proximal tubules, the nervous 
system glial cells and the small bowel jejunal brush 
border [27,28]. At the jejunal brush border the pro-
tein is better known as FOLH1 and here it converts 
dietary folate (pteroylpolyglutamate) to monogluta-
mated folate [29,30]. In the nervous system, however, 
PSMA carries out its N-acetylated alpha-linked acidic 
dipeptidase (NAALADase) function and hydrolyses 
N-acetylaspartylglutamic acid (NAAG), the most 
abundant peptide neurotransmitter in the mammalian 
nervous system [30,31]. The presence of PSMA in the 
prostate and proximal tubules of the kidneys is not yet 
understood but it has been suggested that this could 
be due to the reuptake of folate in the kidneys and 
the release of monoglutamated folates into the seminal 
fluid [30].
The cell surface expression of PSMA has been shown 
to increase directly in cancers of higher grade, metas-
tases, prostate cancer which is castration-resistant and 
cancers giving an adverse clinical outcome [32,33]. Fur-
thermore, PSMA expression was observed to decrease 
in the prostate cancer cell line, LNCap, when incu-
bated with androgen dihydrotestosterone and, con-
versely, cells grown in androgen-stripped media dis-
played increased PSMA expression [34]. It is clear that 
increased expression and enzymatic activity of PSMA 
in aggressive tumors are telling of a selective advan-
tage bestowed by PSMA upon tumor cells and this 
 contributes to prostate carcinogenesis [35].
PSMA has also been reported to be expressed in the 
neovasculature of a considerable majority of malignant 
solid tumors (bladder, breast, kidney pancreas, lung 
and melanoma), but not in the corresponding normal 
vasculature [36].
PSMA has been identified as an excellent target for 
imaging and therapy of cancer for several reasons. The 
specificity of its expression is a key factor, with only a 
limited number of normal tissue types expressing the 
protein, along with PSMA’s large extracellular region 
allowing therapeutics to be exclusively targeted to the 
Table 1. Clinical trials targeting mouse double minute 2 for cancer treatments.
Intervention Target Cancer type targeted Affiliates Trials stage Current status
Biological: CD105/Yb-1/
SOX2/CDH3/MDM2 
multiplasmid vaccine
MDM2-
expressing 
tumor cells
Advanced solid tumors, 
lymphomas
University of 
Washington
Phase I Not yet recruiting
Drug: RO6839921 MDM2-p53 
interaction
Neoplasms, leukemia, 
myelodysplastic syndrome
Hoffman-La 
Roche
Phase I Recruiting
Drug: DS-3032 MDM2-p53 
interaction
HER2-negative stage III–IV Daiichi Sankyo 
Inc.
Phase I Recruiting
Drug: RO5045337 MDM2-p53 
interaction
Soft tissue sarcoma, 
neoplasms, leukemia
Hoffman-La 
Roche
Phase Ib Active, not recruiting/
Completed
Drug: RO5503781 MDM2-p53 
interaction
Neoplasms Hoffman-La 
Roche
Phase I Completed
Drug: 
thioureidobutyronitrile
p53 activator Solid Tumors Cellceutix 
Corporation
Phase I Recruiting
Drug: HDM201 MDM2-p53 
interaction
Advanced tumors 
(TP53wt) liposarcoma
Novartis 
Pharmaceuticals
Phase I Recruiting
Drug: CGM097 MDM2-p53 
interaction
Solid tumors with p53 wt 
states
Novartis 
Pharmaceuticals
Phase I Recruiting
Drug: SAR405838 MDM2-p53 
interaction
Neoplasm malignant Sanofi Phase I Ongoing
Drug: MK-8242 MDM2-p53 
interaction
Solid tumors Merck Sharp & 
Dohme Corp.
Phase I Completed
Drug: AM 232 MDM2-p53 
interaction
Advanced solid tumors, 
multiple myeloma
Amgen Phase I Recruiting
1356 Biomark. Med. (2015) 9(12) future science group
Review    Bradbury, Jiang & Cui
tumor region and malignant cells. The fact that PSMA 
is a transmembrane protein is also important, as its 
extracellular region can be easily targeted by therapeu-
tics. Also, the presence of an internalization sequence 
within the protein means that therapeutics targeted at 
PSMA could be internalized through binding. Finally, 
PSMA’s peptidase activities, means that it could be 
involved in the processing of a pro-drug targeted at 
tumor cells [36–38]. Therefore, there is a very strong case 
for the use of PSMA as a biomarker and therapeutic 
target in the fight against cancer.
PSMA as a biomarker
Since prostate cancer tissues shows high PSMA expres-
sion and increased enzymatic activity of PSMA com-
pared with normal and benign hyperplasia prostate 
tissues [39,40] the use of PSMA as a biomarker for pros-
tate cancer is under investigation. A direct correlation 
has been identified in adenocarcinomas between the 
expression of PSMA and Gleason score, which is used 
to stage prostate cancer [40]. A study by Ross et al. sug-
gests that PSMA could act as a biomarker for prog-
nosis as it shows a significant correlation with adverse 
prognostic factors such as tumor grade, aneuploidy, 
biochemical recurrence and pathological stage [32].
The current standard for early detection of pros-
tate cancer involves a digital rectal examination and a 
serum test for prostate-specific antigen (PSA). Despite 
its use, there is no definite level of PSA which can 
actively distinguish between men with prostate cancer 
and those with a benign hyperplasia, leading to false-
positive results and overtreatment of men with limited 
disease [33].
PSMA immunohistochemistry was seen to have a 
higher (84%) sensitivity than PSA (58%) in staining 
of tissues from metastatic sites. Strong, diffuse staining 
was seen in 17 of 19 cases of metastatic prostate can-
cers, compared with 13 from PSA staining. Positivity 
for either of the molecules was seen in 89% of meta-
static prostate cancer and this combination immuno-
histochemistry was slightly more sensitive than that of 
PSMA alone, indicating that a combination of PSMA 
and PSA immunohistochemistry could be a beneficial 
prognostic assessment for patients [41].
Quantification of PSMA and PSA levels in periph-
eral blood showed significant differences among BPH, 
locally confined prostate cancer and metastasized pros-
tate cancer in expression of PSA and PSMA. It was 
found that one cancer cell could be detected in 2 × 107 
mononuclear cells [42].
The first clinical agent targeting PSMA in prostate 
cancer was the monoclonal antibody 7E11/CYT-356, 
which was labeled with Indium-111 and known as 
111In-capromab or ProstaScint [30,43,44]. The sensitivity 
and specificity of the antibody has differed in stud-
ies, with an average sensitivity of 60%, a specificity of 
70%, a positive predictive value of 60% and a nega-
tive predictive value of 70% [45,46]. These poor results 
could be a consequence of 111In-capromab recognizing 
an intracellular epitope, and therefore only binding 
molecules in cells with a damaged cell membrane [30].
This led to the development of second-generation 
antibodies which can bind to the extracellular region 
of PSMA and thus could be superior to the capromab 
pendetide. One of these developed antibodies, J591, 
has shown potential in imaging primary prostate can-
cer, as well as bone metastases. Clinical trials with 
99mTc-labeled J591 established detection of primary 
prostate cancer, as well as prostate bed recurrence 
and distant metastases, again, including metastasis to 
bone [30,47]. Several other developed monoclonal anti-
bodies (3/A12, 3/E7 and 3/F11) bind to different epit-
opes of PSMA [35]. A study using 64Cu-3/A12 for PET 
imaging of prostate cancer xenograft showed a good 
tumor-to-background ratio [44]. A fourth monoclonal 
antibody targeting PSMA, 3C6, has been labeled with 
111In for imaging in prostate cancer [48].
Radiolabeled PSMA inhibitor N-[N-[-(S)-1,3-di-
carboxypropyl]carbamoyl]-S-[11C]methyl-l-cysteine 
(DCFBC) has been successfully used in PET imaging 
of xenografts expressing PSMA [49]. The molecule was 
labeled with 18F, with studies into its biodistribution 
and imaging showing a high uptake of 18F-DCFBC 
in PSMA-positive tumors but slight or no uptake in 
tumors negative for PSMA [50]. Urea-based com-
pounds have also been identified as possible targets for 
imaging of prostate cancer with PET and SPECT [51]. 
MIP-1095 and MIP-1072, which are small-molecule 
inhibitors targeting PSMA, have shown a high affinity 
for PSMA and their uptake when labeled with 123I has 
been successfully imaged by SPECT [52,53].
PSMA as a therapeutic target
PSMA has been exposed as an attractive therapeutic 
target due to its expression being 100- to 1000-fold less 
in normal cells in comparison to prostate carcinoma 
cells [54]. So far, antibody-based radiotherapy, anti-
body-drug conjugates (ADC), PSMA-targeted pro-
drug therapy and PSMA-based immunotherapy have 
been investigated [30].
The leading PSMA antibody-based radiotherapeutic 
is Lutetium-177 J591, which showed acceptable toxic-
ity and excellent metastatic site targeting in a Phase 
I clinical trial [55]. A recent Phase II clinical trial uti-
lized Lutetium-177 J591 in patients with metastatic 
castration-resistant prostate cancer [56]. Just less than 
60% of patients showed a decrease in PSA levels with 
1/10 showing a reduction of more than half and the 
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Table 2. Clinical trials utilizing prostate-specific membrane antigen for cancer imaging and treatments.
Intervention Use Cancer type 
targeted
Affiliates Trials stage Current status
Drug: 68Ga-PSMA Imaging/diagnosis Prostate cancer Ebrahim Delpassand Phase II Recruiting
Drug: PSMA ADC 2301 Treatment mCRPC Progenics 
Pharmaceuticals, Inc.
Phase II Completed
Drug: PSMA ADC BrUOG 263 Treatment Glioblastoma 
multiforme, 
gliosarcoma
Heinrich Elinzano, MD Phase II Active, not 
recruiting
Drug: PSMA ADC 1301 Treatment mCRPC Progenics 
Pharmaceuticals, Inc.
Phase I Completed
Biological: peptide vaccine/
drug: poly IC-LC
Vaccine treatment Prostate cancer H. Lee Moffitt Cancer 
Center and Research 
Institute
Phase I Active, not 
recruiting 
(has results)
Drug: Anti-PSMA designer 
T cells
Treatment Prostate cancer Roger Williams Medical 
Centre
Phase II Active, not 
recruiting
Biological: rsPSMA protein 
plus alhydrogel vaccine
Vaccine treatment Prostate cancer Memorial Sloan–
Kettering Cancer Centre
Phase I Completed
Biological: anti-PSMA 
monoclonal antibody 
MDX1201-A488
Imaging/diagnosis Prostate cancer City of Hope Medical 
Centre
Phase I Recruiting
Biological: gene modified T 
cells
Treatment Prostate cancer Roger Williams Medical 
Centre
Phase I Active, not 
recruiting
Biological: engineered 
autologous T cells/drug: 
cyclophosphamide
Treatment Prostate cancer Memorial Sloan–
Kettering Cancer Centre
Phase I Recruiting
Biological: human PSMA 
plasmid DNA vaccine
Treatment Kidneycancer Memorial Sloan–
Kettering Cancer Centre
Phase I Active, not 
recruiting
Drug: 18F-DCFBC Imaging/diagnosis Prostate cancer Sidney Kimmel 
Comprehensive Cancer 
Center
Phase II Active, not 
recruiting
Device: ProxiScan 
(scintigraphic rectal probe)
Imaging/diagnosis Prostate cancer Sidney Kimmel 
Comprehensive Cancer 
Center
Phase I Completed
Biological: PSMA prostate 
cancer vaccine/IL-12
Treatment Prostate cancer University of Chicago Phase II Completed
Biological: PSMA/PRAME 
(MKC1106-PP)
Treatment Advanced 
cancer
Mannkind Corporation Phase I Completed
Drug: 123I-MIP-1072 Imaging/diagnosis Prostate cancer Molecular Insight 
Pharmaceuticals, Inc.
Phase I Terminated
Drug: 89Zr-J591 Imaging/diagnosis Glioblastoma 
multiforme, 
gliosarcoma
Memorial Sloan–
Kettering Cancer Centre
Phase I Recruiting
Drug: 111-In capromab 
pendetide
Imaging/diagnosis Prostate cancer Molecular Insight 
Pharmaceuticals, Inc.
Phase I Completed
Biological: androgen 
ablation/dendritic cell 
vaccine
Treatment Prostate cancer Pawel Kanlinkski Phase I Recruiting
Drug: 89Zr-DFO-huJ591 Imaging/diagnosis Prostate cancer Memorial Sloan–
Kettering Cancer Centre
Phase II Active, not 
recruiting
Data taken from [63].
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therapeutic showed accurate targeting of metastatic 
sites [38]. The higher concentration used in the trials 
(70 mCi/m2) led to longer survival of patients (almost 
22 months, compared with 12 months), but resulted 
in increased grade 4 hematologic toxicity and platelet 
transfusions [30,56].
J591 antibody has also been utilized in the produc-
tion of ADC, which involves the linking of a drug or 
toxin to an antibody [38]. MLN2704 is an antimicrotu-
bule agent which has been conjugated to J591. Phase I 
studies in over 20 patients showed PSA levels dropped 
by more than half in two patients, although grade 3 
toxicities occurred in three of the patients [30,57]. A 
multicentre Phase II/III clinical trial undertaken in 62 
men with metastatic castration-resistant prostate can-
cer showed stabilization or decline in PSA in a majority 
of patients; however, limitation of treatment occurred 
due to toxic effects of the compound [30,38].
Work has been undertaken in xenograft LNCaP 
mice, using an immunotoxin consisting of the anti-
PSA mAb E6 and deglycosylated ricin A, showing 
reduced tumor growth [38,58]. Another group coupled 
melitten-like peptide 101 to J591 and also saw a signifi-
cant tumor growth inhibition in mice [38,59]. Mono-
methylauristatin E (MMAE) has also been conju-
gated to a mAb which recognized the PSMA external 
domain [60].
Recently, a group engineered a prodrug for tumor 
endothelial cells in prostate cancer therapy [61]. Their 
work involved the coupling of a PSMA-specific pep-
tide to thapsigargin (inhibitor) of the sarcoplasmic/
endoplasmic reticulum calcium adenosine triphos-
phate (SERCA) pump. SERCA is a vital cellular pro-
tein which is essential for the viability of all cell types. 
Before cleavage of the PSMA-specific molecule, the 
conjugate is inactive. However, post-cleavage, local 
SERCA inhibition ensues [30]. Preclinical xenograft 
models treated with thapsigargin showed significant 
prostate cancer tumor regression at doses which were 
modestly toxic to the host [61].
The use of immunotherapy in oncology has been 
long utilized, but only recently has work on PSMA 
as a target begun to be investigated [38]. This type of 
therapy is based on the concept that IL-2 stimulates 
natural killer cells, thus enhancing antibody-depen-
dent cellular cytotoxicity. A Phase II trial of the anti-
PSMA monoclonal antibody J591 was undertaken in 
patients with recurrent prostate cancer for 8 weeks, 
with patients receiving continuous low-dose subcuta-
neous IL-2 every day, with infusions of J591 weekly. Of 
17 patients, nine had stable PSA, with declines of up to 
34%. The therapy was well tolerated and the toxicity 
was low, with non-progressors showing a trend with 
significant natural killer (NK) cell expansion [30,38,62].
Thus, although PSMA-targeted therapy is yet to 
yield clinically important effects on the survival of 
patients without severe side effects ensuing, several 
fields are currently under study and as our molecular 
techniques and our understanding of tumor biology 
become more advanced, PSMA-therapeutics are likely 
to play an important role in the development of treat-
ment for cancer patients [30] (clinical trials of PSMA 
as a biomarker and therapeutic target summarized in 
Table 2 [63]).
Tumor-associated angiogenesis mediated by 
MDM2 & PSMA
Vascular endothelial factor (VEGF) is a potent angio-
genic factor that plays an important role in regulating 
normal physiological and pathological angiogenesis. 
Correctly timed expression of VEGF at appropriate 
levels is crucial for normal development of vascula-
Intervention Use Cancer type 
targeted
Affiliates Trials stage Current status
Drug: G-202 Imaging/diagnosis Glioblastoma 
multiforme, 
advanced 
hepatocellular 
carcioma
GenSpera, Inc. Phase II Recruiting 
Phase II
Drug: 99mTc MIP 1404 Imaging/diagnosis Prostate cancer Molecular Insight 
Pharmaceuticals, Inc.
Phase I Active, not 
recruiting
Radiation: [89Zr]Df-IAB2M Treatment Prostate cancer ImaginAb, Inc. Phase II Recruiting
Drug: EC1169 Treatment Prostate cancer Endocyte Phase I Recruiting
Drug: GVAX and ipilimumab Treatment mCRPC VU University Medical 
Center
Phase I Terminated
Data taken from [63].
Table 2. Clinical trials utilizing prostate-specific membrane antigen for cancer imaging and treatments (cont.).
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ture and homeostasis, but also vital for solid tumor 
growth. VEGF is highly expressed in solid tumors and 
is required for the development and maintenance of 
blood vessels within the tumor, which is a prerequisite 
for successful tumor growth and metastasis.
A co-expression study was undertaken to evaluate 
the correlated expression of MDM2 and VEGF, find-
ing that, over eight different cancer cell lines, higher 
MDM2 expression meant higher VEGF mRNA, with 
the cell lines with lost p53 function showing highest 
VEGF levels [64]. They verified their findings further 
by inhibiting MDM2 using a specific MDM2-specific 
antisense oligonucleotide (HDMAS5) and saw a sig-
nificant decrease in VEGF mRNA and protein levels. 
Finally, they proved that transfecting the MDM2 gene 
in the prostate cancer cell line, LNCaP, produced a 
cell line overexpressing MDM2 and VEGF. The same 
group then identified MDM2 as a regulator of VEGF 
expression in cancer cells. HUVECs were treated with 
tumor-conditioned media from HMAS5-treated can-
cer cells. They found that VEGF release from cells 
and VEGF-dependent angiogenesis were significantly 
reduced in vitro [65].
Hypoxia-inducible factor 1 (HIF-1) is a heterodi-
meric transcription factor which generates a response 
to oxygen deprivation due to hypoxic conditions. 
Active HIF-1 is comprised of two subunits: HIF-1β 
is constitutively expressed in the cell, however, under 
normoxic conditions HIF-1α is covalently modified by 
prolyl hydroxylases, allowing VHL E3 ubiquitin ligase 
to polyubiquitinate and thus targets HIF-1α for deg-
radation [66,67]. Factor inhibiting HIF-1 (FIH-1) can 
also hydroxylate HIF-1α, preventing coactivator bind-
ing and so inhibiting transcription of target genes [68]. 
Following a decrease in cellular oxygen levels, the rates 
of hydroxylation are decreased, VHL does not bind, 
HIF-1α is stabilized and the HIF-1 the heterodimer 
can form [69]. Overexpression of HIF-1α has been 
linked to angiogenesis, tumor invasion and a poor 
prognosis in many types of cancer [70–73]. The HIF-1 
transcription factor binds to the 5′ flanking sequence 
of vegf and is essential for the transactivation of vegf 
during hypoxia (see Figure 2).
It has been known for some time that hypoxia is a 
physiological inducer of tumor suppressor p53, with 
p53 protein levels increasing under hypoxic condi-
tions [74]. Since MDM2 is the most important negative 
regulator of p53, many groups began to look into the 
precise mechanism of the interaction between hypoxia 
and p53, and whether MDM2 was involved [68,75–84].
In 2005, a study showed that MDM2 positively 
activates HIF-1α in hypoxic tumor cells. Co-immu-
noprecipitation showed that MDM2 precipitates 
with HIF-1α, completely independently of p53 [75]. 
Evidence toward the involvement of MDM2 in the 
regulation HIF-1α expression under hypoxic con-
ditions came from Lau et al. [76], who found that 
inhibitory effects on HIF-1α by the anti-cancer drug 
3-(5’-hydroxymethyl-2’-furyl)-1-benzyl indazole (YC-
1), was MDM2-dependent and that overexpression of 
MDM2 reversed its inhibitory effects. A very recent 
study also suggested that, under hypoxic conditions, 
MDM2 is capable of ubiquitinating HIF-1α with its 
E3 ubiquitin ligase domain in a PTEN/PI3K-depen-
dent manner. The group’s results suggested that the 
PI3K-AKT signaling axis is a requirement for the pres-
ervation of HIF-1α stability during hypoxia [69] (see 
Figure 2).
Another study showed that nutlin-3 conferred anti-
angiogenic activity. It was found that nutlin-3 dose-
dependently suppressed the total tube length and 
the number of capillary connections developed from 
HUVECs. Also, the migration of endothelial cells 
was shown to be significantly inhibited by nutlin-3 in 
response to various chemoattractants [77]. In the same 
year, two more reports were published demonstrat-
ing the inhibition of HIF-1α by nutlin-3, leading to 
inhibited VEGF production and thus angiogenesis in 
tumors [78,79]. Lee et al. [80] then suggested a mecha-
nism through which this occurred after finding that 
nutlin-3 downregulated HIF-1α in p53-positive cells 
but also functionally inactivated HIF-1α in p53-neg-
ative cells. Of these two occurrences, they found that 
the second mainly contributed to VEGF suppression 
by nutlin-3. It was reported that MDM2 competes 
with FIH which is a regulator of HIF-1α, by bind-
ing its C-terminal transactivation domain (CAD). 
FIH hydroxylates Asn803 in the CAD domain under 
normoxic conditions. However, when conditions are 
hypoxic, this hydroxylation is inhibited due to the 
limited oxygen and so HIF-1α becomes stable and 
active [68,81]. When MDM2 competes for binding of 
the CAD of HIF-1α, this hydroxylation is inhibited 
and so p300 is recruited. They found that nutlin-3 
reinforced the FIH-mediated inactivation of HIF-1α 
through inhibiting any interaction between CAD and 
MDM2 [80]. This theory is in direct contrast to the 
report by LaRusch et al. [78], who reported that the 
N-terminal domain of HIF-1α was needed for bind-
ing of MDM2. This could imply that each domain of 
HIF-1α interacts individually in different ways with 
MDM2 or they cooperate to bind MDM2.
Therefore, it is widely accepted that hypoxia induces 
VEGF transcription through induction of HIF-1α. 
However, in 2011, a group set out to investigate the post-
transcriptional regulation occurring, in which HIF-1α 
does not seem to be important [82]. Their work followed 
on from a study which showed that in rat cardiac myo-
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Figure 1. Hypothesized mouse double minute 2 and prostate-specific membrane antigen interaction through 
folate metabolism in aggressive tumors. PSMA metabolizes dietary folate to produce dihydrofolate, which is then 
converted to tetrahydrofolate by DHFR. DHFR is regulated by MDM2 through its RING-finger dependent E3 ligase 
activity, which is known to also regulate the p53 tumor suppressor. The p53 tumor suppressor is regulated by 
methylation of DNA, RNA, histones and lipids, which is governed by folate metabolism. Therefore, we hypothesize 
that in cancer cells, PSMA may be involved in the expression or activity of MDM2 through aberrant regulation of 
p53 methylation via folate metabolism.
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cytes hypoxia can induce VEGF steady-state mRNA 
25-fold; however, the hypoxia-mediated transcription 
rate of VEGF increases just 3.1-fold [85]. Their results 
showed that the RING domain of MDM2 can bind to 
AU-rich elements of the VEGF 3′ untranslated region 
(UTR) and regulate VEGF mRNA stability and thus 
its translation. Interestingly, they also demonstrated 
that during hypoxia, MDM2 was dephosphorylated 
and translocated to the cytoplasm from the nucleus, 
where it was able to induce high levels of VEGF in can-
cer cells [82]. The same group then undertook a study to 
elucidate whether p53 played a role in the interaction 
between MDM2 and VEGF. They did this through the 
use of two cell lines, MCF-7 which expresses wild-type 
p53 and MDA-MB-468, which expresses mutant p53. 
They studied the effect of nutlin-3 and anti-MDM2 
antisense oligonucleotide (ASO), on these cell lines and 
saw that ASO significantly inhibited the VEGF tran-
script and protein levels in a dose- and time-dependent 
manner, whereas nutlin-3 had no effect. The effect 
of hypoxia was also studied, and it was observed that 
ASO treatment significantly inhibited HIF-1α expres-
sion at 3, 6 and 12 h of hypoxia in both cell lines. An 
inhibitory effect on HIF-1α was also seen in the nut-
lin-3 treated MCF-7 (wild-type p53) but not in MDA-
MB-468 (mutant p53). The group used siRNA tar-
geted at HIF-1α as well as ASO treatment, and found 
that HIF-1α only seems to have a role in VEGF produc-
tion in early hypoxia (at 6 h, but not at 48 h). HIF-1α 
siRNA did not reverse the inhibitory effect of ASO on 
VEGF production. Therefore, the group surmised that 
ASO downregulates hypoxia-induced VEGF produc-
tion via a HIF-1α-independent mechanism. When the 
same experiment was undertaken using nutlin-3, it was 
seen that nutlin-3 significantly inhibited the level of 
secreted VEGF from the MCF-7 cells at early hypoxia. 
When the cells were transfected with HIF-1α siRNA, 
nutlin-3 failed to inhibit VEGF production. This exhib-
its that the effect of nutlin-3 on VEGF regulation in 
early hypoxia is HIF-1α-dependent. ASO treatment of 
mice with tumors of each cell type showed a substantial 
decrease in serum VEGF levels, measured by ELISA. 
On the other hand, nutlin-3 treatment produced little 
effect on VEGF production [83].
A very recent study investigated the precise mecha-
nism supporting the induction of VEGF transcrip-
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Figure 2. Proposed interplay roles of mouse double minute 2 and prostate-specific membrane antigen in tumor invasion through 
multiple signaling pathways. MDM2 and PSMA have both been linked to MMP-2 and MMP-9. HIF-1α is known to regulate the MMP 
inhibitor, TIMP-1. Since MDM2 activates HIF-1α, both PSMA and MDM2 could play a role in MMP regulation during hypoxia. MDM2 
inactives p53 which is known suppress transcription of VEGF. The P13K and PAK pathways in endothelial cells can be activated directly 
by VEGF and also indirectly by PSMA through binding with integrin. Therefore MDM2 and PSMA may mediate angiogenesis which 
could permit the exertion of a synergetic pro-angiogenic effect between the proteins.
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tion by MDM2. They used prostate cancer cell lines 
LNCaP and MDM2 transfected LNCaP (LNCaP-
MST). As expected, they found that VEGF transcrip-
tion was significantly higher in the LNCaP-MST cells 
compared with the nontransfected LNCaP [84]. Acti-
vation of the PI3K-mTOR pathway has previously 
been reported upon increase of VEGF expression in 
normoxic and hypoxic conditions [65]. Since HIF-1α 
is required as a primary member of this pathway, it 
is generally assumed that activation of the pathway 
is more effective under hypoxic conditions, in terms 
of induction of VEGF transcription. Yet, this study 
showed that in the LNCaP-MST cells, the PI3K-
mTOR pathway seems to be activated and the basal 
HIF-1α appear high. They reported that MDM2 
seemed to be triggering an elevated level of HIF-1α, in 
line with increasing expression of VEGF in normoxic 
cells, even when hypoxic conditions are lacking. The 
data presented also suggested that STAT3 and NF-κB 
may play important roles in MDM2-mediated acti-
vation of VEGF transcription, since their levels were 
increased in the LNCaP-MST cells compared with the 
nontransfected LNCaP cells [84].
It has also been suggested that p53 can negatively 
regulate VEGF expression. In 2000, Ravi et al. [86] 
claimed that homozygous deletion of p53 in human 
colon cancer cells promoted neovascularization and 
growth of xenograft tumors in nude mice. They 
showed that upon loss of p53, HIF-1 protein levels are 
enhanced and so VEGF expression is augmented. It 
was also demonstrated that forced HIF-1α expression 
in p53-expressing cancer cells promotes the expres-
sion of VEGF and this leads to neovascularization of 
tumor xenografts. Therefore, the group concluded that 
p53 acts as a molecular chaperone to HIF-1α, facili-
tating its recognition by MDM2 for ubiquitination. 
This work was disputed by a later study [75] which sug-
gests that the group’s results may be due to the use of 
hypoxia-mimicking agents such as cobalt and thus the 
proteins in complex could change.
In conclusion, despite the great amount of studies 
undertaken in order to elucidate the role of MDM2 in 
both angiogenesis and hypoxia, the precise mechanisms 
are yet to be exposed. It is widely accepted that MDM2 
and VEGF levels are coordinated in cancer and that 
HIF-1α increase can upregulate VEGF transcription 
during hypoxia. It has been proved many times that 
MDM2 and HIF-1α interact during hypoxia, although 
whether this is a direct or indirect interaction, and 
whether it involves p53 tumor suppressor is under scru-
tiny. It has also been suggested that a second layer of 
regulation occurs between MDM2 and VEGF, at post-
transcriptional level, independent of HIF-1α. There-
fore, perhaps there are different points of regulation of 
VEGF levels by MDM2 during hypoxia and HIF-1α 
and p53 may play a role in some, but not others.
In terms of links of PSMA to VEGF, there are dif-
fering reports. A report by Tsui et al. [87] claimed that 
there was a correlation between PSMA and VEGF 
expression in the tumors of xenograft mice, when 
immunohistological analysis was undertaken. Forced 
PSMA expression in a prostate cancer cell line, RM-1 
and quantification of secretion of VEGF by cells, led to 
the conclusion that stable transfection of PSMA pro-
moted VEGF release. When these cells were injected 
into mice, immunohistochemistry was performed and 
VEGF levels were seen to be significantly higher in the 
mice injected with the cells expressing PSMA [88].
Since it is found in the neovasculature of many 
tumors, PSMA is thought to regulate angiogenesis. In 
2006, a group demonstrated that PSMA is required 
for angiogenesis in vivo and invasion of endothelial 
cells in vitro, where it was exhibited to be involved 
in laminin-specific signaling and regulation of the 
dynamics of the cytoskeleton through the Rho 
GTPase effector molecule p21-activated kinase 1 
(PAK-1). The group hypothesised that PSMA par-
takes in an autoregulatory feedback loop where, in its 
active state, it increases integrin signal transduction, 
PAK activation, followed by endothelial cell adhesion 
and invasion. This process leads to the dissociation 
the PSMA/filamin complex and a decrease in PSMA 
activity and therefore integrin-β1 activity is held in 
check [89] (see Figure 2).
In a subsequent study, the same group then went 
on to assess the role of PSMA in ocular neovascular-
ization. To do this they used an oxygen induced reti-
nopathy model (OIR) and it was observed that, after 
an initial decrease in retinal PSMA mRNA, transcript 
levels were progressively increased over the time of the 
relative hypoxia. Vessel formation was then assessed in 
the retina of PSMA null mice under these conditions 
of relative hypoxia. Again, it was seen that the loss of 
PSMA in these mice did not affect the development 
of normal retinal vasculature. However, mice under-
going OIR showed a remarkable difference between 
PSMA null and wild-type. The capillaries in the mid-
periphery formed a dense, honeycomb of close vessels. 
In comparison, retinas from PSMA null animals after 
OIR showed a vascular pattern which closely resem-
bled the normal structure, with less avascular area in 
the central region and more highly branched capillaries 
in the periphery. It was also seen that, in comparison 
to the wild-type, PSMA null mice vessels were better 
perfused and more functional. Finally, the study eval-
uated the use of 2-(phosphonomethyl)pentanedioic 
acid (2-PMPA) PSMA inhibitor in wild-type mice 
and obtained similar results. Therefore, the absence of 
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PSMA seems to lead to a less pathogenic phenotype in 
the retina. The involvement of PSMA in angiogenesis 
through this mechanism was seen to be independent 
of VEGF [90].
It is certain that PSMA is involved in angiogene-
sis; however, the precise mechanism by which PSMA 
exerts its effect is unknown. PSMA has been linked 
to VEGF levels in some reports, with increased and 
decreased PSMA levels being reflected in VEGF 
expression. However, a group who have released a 
number of related papers on the subject of PSMA in 
angiogenesis claim that the involvement of this pro-
tein is VEGF-independent. This suggests that PSMA 
may also play a number of roles in angiogenesis, some 
involving VEGF, others not.
Participation of MDM2 & PSMA in tumor 
invasion & metastasis
Due to the high expression of PSMA and MDM2 a 
number of cancer types, their roles in the invasion 
and subsequent metastasis of tumors have been stud-
ied. Migration and invasion through the extracellular 
matrix are reliant on the matrix metalloproteinases 
(MMPs) which are zinc-dependent remodeling endo-
peptidases implicated in many pivotal roles in tumor 
growth and the multistep processes of invasion and 
metastasis. Different members of the MMP family 
exert contradicting roles at various stages of cancer 
progression [91].
The most obvious feature of MDM2 involvement 
in the progressive properties of cancer is its interac-
tion with p53. The ability of MDM2 to block p53 
activity is exploited by tumor cells. However, there 
are other ways in which MDM2 contributes to the 
progression of cancer. It was shown that in breast 
cancer cells MDM2 can decrease E-cadherin protein 
level through ubiquitination and ectopic expression of 
MDM2 increases cell–cell dissociation, invasion and 
cell motility [92]. A study into patients with malignant 
melanoma showed that MDM2 expression level was 
directly associated with the thickness of a tumor and 
weakly with  invasion level [93].
Immunohistochemical staining of invasive ductal 
breast carcinoma (IDC) showed a significant correla-
tion between MDM2 and MMP-9 expression. In vitro 
studies in MDA-MB-231 and MCF-7 breast cancer 
cell lines have shown that siRNA targeted at MDM2-
targeted siRNA significantly decreased cell invasion, 
migration and proteolysis, with the opposite seen in 
cells overexpressing MDM2. MDM2 overexpression 
in these cells was seen to induce MMP-9 expression 
in a dose-dependent manner [94]. A slightly later study 
also linked the expression of MDM2 and MMP-9 in 
the oncogenesis of lung cancer in rats [95] (see Figure 2).
A paper by Ghosh et al. [96] showed that, surpris-
ingly, in prostate cancer cells, ectopic expression 
of PSMA in the PSMA-negative cell line PC-3 cells 
reduced their invasiveness. On the other hand, they 
found that knockdown of PSMA in the PSMA-pos-
itive cell line, LNCaP, increased their invasiveness 
fivefold. PSMA mutants lacking the carboxypepti-
dase activity of the protein were produced and showed 
that this reduced the impact of PSMA expression on 
invasiveness. Another study involving the injection of 
the mouse prostate cancer cell line RM-1 with stable 
expression of PSMA into mice showed the formation 
of lytic bone lesions and distinct MMP-9 expression 
compared with the control [88].
Recently, it was found that the sequential digestion 
of laminin, a predominant component of the extracel-
lular matrix (ECM), occurs through PSMA working 
downstream of MMP-2, generating small peptides 
which enhance the invasive and adhesive abilities 
of HUVECs in vitro, providing evidence that these 
peptides activate adhesion through integrinα
6
β
1
 and 
FAK. It was suggested that since PSMA is a glutamate-
specific peptidase, cleavage of a laminin-derived pep-
tide substrate could modify the overall charge of the 
 peptide and so facilitate integrin binding [97].
Another study has linked the expression levels of 
PSMA and MDM2 in no uncertain terms. LNCaP 
(PSMA positive) and PC3 (PSMA negative) cell lines 
were used to assess metastasis-related genes which were 
downregulated in cells with silenced PSMA. It was 
found that MDM2 transcript levels were decreased 
over 80-fold following PSMA silencing. This paper 
also indicated that the treatment of the LNCaP cell line 
with PSMA-targeted siRNA led to an upregulation of 
MMP-3 and -13, and a downregulation of MMP-2 [98] 
(see Figure 2). This decrease has also been shown in 
breast cancer cell lines in our own laboratory (unpub-
lished data). Since the degradation of the extracellular 
matrix and basement membrane by MMPs is pivotal 
to whether a tumor infiltrates and metastasises, it may 
be deduced that PSMA could interplay with MDM2 
to regulate MMP secretion. This theory is supported 
by the many reports linking both proteins to a number 
of MMPs.
In conclusion, if Xu et al. [98] and our own find-
ings concerning the correlated expression of MDM2 
and PSMA are correct, it seems that conflicting 
data exists regarding invasion capacity as a result of 
MDM2 and PSMA knockdown and overexpression. 
Ghosh et al. [96], claimed that PSMA increase reduced 
in vitro invasion of prostate cancer cell lines, and vice 
versa; however, Chen et al. [94] saw that MDM2 decrease 
caused a decrease in invasion, and vice versa, in breast 
cancer cell lines. Since both proteins have been reported 
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to have correlations with MMP-9 [88,94,95] and PSMA 
has been linked to MMP-2 [97,98], it would be expected 
that a decrease in transwell cellular invasion would be 
seen. This apparent contradiction of results could be 
explained by the fact that different cell lines were used 
for each study, and these cancer cells were derived from 
very different areas of the human body (prostate and 
breast). However, it could also be the result of both 
proteins being decreased in expression when PSMA 
levels are decreased, and only MDM2 protein being 
decreased when the mdm2 gene is targeted, as so far no 
studies have been published which show the expression 
levels of PSMA when the mdm2 gene is knocked down. 
Therefore, the difference in results seen could high-
light the pathways in which MDM2 and PSMA inter-
act, and those in which MDM2 works alone. This may 
mean that when PSMA levels are decreased, factors 
that increase invasion are produced in the cells and this 
is a stronger force than those factors that are decreased 
when MDM2 levels are reduced, which would other-
wise decrease invasion. Further work in our own and 
other laboratories will hopefully lead to an explanation 
regarding whether this is the case.
Signaling pathways of MDM2 & PSMA are 
intertwined by DHFR & HIF1α
As aforementioned, PSMA was originally identified as 
FOLH1, named for its important role in folate metabo-
lism. Previously cited studies show that PSMA plays a 
critical role in the progressive properties of cancer. It 
has been found that PSMA expression gives LNCaP 
prostate cancer cells a growth advantage in media 
containing low (<1 nM) and physiological (25 nM) 
folate [99]. The same group then showed that PSMA-
expressing PC-3 cells showed a growth advantage 
 compared with wild-type PC-3 cells.
MDM2 has also been identified to have an involve-
ment in folate metabolism, with its ability to directly 
bind to DHFR and catalyze the monoubiquitination of 
DHFR via its E3 ubiquitin ligase activity and reduce 
DHFR activity within cells, without changing levels of 
steady-state DHFR, in a RING finger-dependent and 
p53-independent manner [100]. DHFR is an important 
folate metabolizing enzyme which reduces dihydrofo-
lic acid (DHF) to tetrahydrofolic acid, using NAPDH 
as an electron donor. Tetrahydrofolic acid can then 
be converted to many types of tetrahydrofolate cofac-
tors using in one-carbon chemistry. This one-carbon 
transfer reaction catalyzed by DHFR is essential for 
DNA synthesis and homocysteine remethylation [101]. 
Changes in the level of DHFR expression and activ-
ity due to genetic polymorphisms can affect a patient’s 
susceptibility to a variety of diseases including cancer. 
Likewise, variability in DHFR expression can affect 
the sensitivity of a patient to anticancer drugs such as 
folate antagonist methotrexate (MTX) [102].
There are two possible mechanisms which could 
explain the role of folate in tumor development and 
metastasis. First, folate deficiency causes a reduction of 
intracellular S-adenosylmethionine (SAM) and there-
fore can alter cytosine methylation in DNA, leading 
to an inappropriate activation of proto-oncogenes and 
induction of malignant [103]. Second, folate deficiency 
could cause an imbalance of DNA precursors, uracil 
misincorporation into DNA and chromosome break-
age. A further link of MDM2 to folate metabolism 
is given in the demonstration that folate deficiencies 
induce DNA strand breaks and hypomethylation 
within the p53 tumor suppressor gene in animal mod-
els, suggesting that the relevance of folate activity stress 
to carcinogenesis could be p53-dependent [104]. There-
fore, the involvement of both MDM2 and PSMA in 
folate metabolism could provide reasoning for their 
important role in cancer progression and their pos-
sible interplay, since the roles of the two are so closely 
 connected within the pathway.
We hypothesize that in cancer cells, PSMA may 
be involved in the expression or activity of MDM2 
through aberrant regulation of p53 methylation via its 
activity in folate metabolism Though this hypothesis 
needs to be fully investigated, it is partially supported 
by a recent microarray analysis previously mentioned, 
which suggests that silencing of PSMA using siRNA 
leads to downregulation of MDM2 expression [98]. 
Work by Yao et al. [99] also supports this theory, with 
their studies showing that increased PSMA expres-
sion in conditions of low or physiological folate leads 
to a growth advantage of prostate cancer cell lines. 
This work could imply that increased PSMA, means 
upregulated p53 methylation, greater MDM2 expres-
sion and thus elevated cell growth. Further, DHFR 
has been considered as a target of second-line cancer 
chemotherapy, due to its role in tetrahydrofolate syn-
thesis, which is essential for cellular synthesis of DNA, 
RNA, thymidylates and proteins. As mentioned, this 
leads DHFR to be highly sensitive to tetrahydrofolate 
analogs such as methotrexate (MTX) [105]. Therefore, 
it may be possible that MDM2 inhibition sensitises 
the effects of certain DHFR-targeted therapy, or pro-
motes the function of PSMA in cancer cells through 
the response of DHFR (hypothesis of interplay 
 summarized in Figure 1).
MDM2 and PSMA have been proved to promote the 
activity of matrix metalloproteinases (MMPs), such as 
MMP-2 and MMP-9, which are secreted by cancer 
cells and degrade the extracellular matrix, allowing 
cells to migrate, invade and move from the primary 
cancer site [88,94,95,97,106]. The endogenous inhibitors 
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of MMP activity are the tissue inhibitors of metallo-
proteinases (TIMPs). Recently, it has been suggested 
in a number of papers that HIF-1α is a regulator of 
TIMPs [107], specifically TIMP-1 [108], and the levels of 
MMP-2 and MMP-9 have been seen to correlate with 
higher levels of HIF-1α in polytetrafluoroethylene 
grafts of patients [109]. Therefore, given the evidence 
that MDM2 activates HIF-1α, we hypothesize that 
both PSMA and MDM2 play a role in the regulation 
of MMPs during hypoxia. Additionally, VEGF induces 
Executive summary
Tumorigenesis & clinical relevance of MDM2
•	 Involved in both p53-dependent and -independent roles in the cell.
•	 Important in transformation of cells and its overexpression frequently observed in many human cancers, 
meaning it is a good therapeutic target.
MDM2 as a therapeutic target
•	 Therapeutics aim to decrease protein levels, thus reactivating p53. Undertaken through: reducing protein 
levels in cancer cells, inhibiting E3 ubiquitin ligase activity or disruption of interaction with p53.
•	 No ideal therapy involving MDM2 has been identified, but studies are ongoing and still viewed as a promising 
target.
Clinical relevance of prostate-specific membrane antigen (PSMA)
•	 Known to play a role in folate metabolism and hydrolyse neurotransmitter N-acetylaspartylglutamic acid.
•	 Expression increases in metastasised and later stage/grade cancers.
•	 Excellent target for therapy: specific expression (prostate, kidneys, nervous system and small intestine), large 
extracellular region, transmembrane protein, internalization sequence and peptidase activity (activation of 
prodrug).
PSMA as a biomarker
•	 Since there is a positive correlation between PSMA and adverse clinical outcome, it has been suggested and 
studied as a biomarker for prostate cancer progression.
•	 More sensitive and specific than PSA detection.
•	 Currently, second-generation antibodies which bind extracellular epitopes are under trial. One of these, J591 
has shown potential in imaging of prostate cancer.
PSMA as a therapeutic target
•	 PSMA has been targeted using many different strategies: antibody-based radiotherapy, antibody-drug 
conjugates, prodrug therapy and immunotherapy.
•	 There is yet to be a clinically important effect on survival in patients due to PSMA-based therapeutics.
Tumor-associated angiogenesis mediated by MDM2 and PSMA
•	 MDM2 and VEGF levels are coordinated in cancer.
•	 HIF1α is regulated by MDM2 and through this can upregulate VEGF expression during hypoxia. It is not known 
if p53 is involved in this interaction.
•	 There may be different points of regulation of VEGF by MDM2 – at gene and protein level – some may involve 
p53, some may not.
•	 PSMA also linked to VEGF in some reports but its involvement in angiogenesis has been said to be VEGF-
independent in others.
•	 PSMA involved in autoregulatory feedback loop in endothelial cells where it increases integrin signal 
transduction, PAK activation, followed by endothelial cell adhesion and invasion.
Participation of MDM2 and PSMA in tumor invasion & metastasis
•	 Both proteins have been linked to MMPs: MMP-2 and MMP-9.
•	 Overexpression of MDM2 has been linked to increased migration and invasion in breast cancer cell lines.
•	 Overexpression of PSMA has been linked to decreased migration and invasion in prostate cancer cell lines.
•	 PSMA and MDM2 expression is linked in prostate cancer cells (published data) and breast cancer cells (our own 
unpublished data), with decreased PSMA protein expression leading to a significant decrease in MDM2 gene 
expression.
The signaling pathways of MDM2 and PSMA are intertwined by DHFR and HIF1
•	 MDM2 linked to DHFR, a key enzyme in folate metabolism.
•	 PSMA could be involved in the expression/activity of MDM2 through aberrant regulation of p53.
•	 MDM2 inhibition may sensitise the effects of certain DHFR-targeted therapy or promote function of PSMA in 
cancer cells through response of DHFR.
•	 PSMA and MDM2 may coordinate to regulate MMPs during hypoxia.
•	 Both MDM2 and PSMA could mediate angiogenesis through PI3K pathways and this could permit exertion of a 
synergetic pro-angiogenic effect between the proteins.
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angiogenesis partly through activation of the P13K sig-
naling pathway in endothelial cells [110] and integrin, 
which is known to be regulated by PSMA in endothe-
lial cells, can also activate P13 through p21-activated 
kinase (PAK) [89]; as well as MDM2 being shown to 
regulate HIF-1α in a PTEN/PI3K-dependent man-
ner [69]. Thus, both MDM2 and PSMA could medi-
ate angiogenesis or, in particular, hypoxia-mediated 
angiogenesis, through PI3K pathways and this could 
permit the exertion of a synergetic pro-angiogenic 
effect between the proteins [40].
Future perspective
Although, to date, no ideal therapeutics targeted to 
MDM2 or PSMA have been identified, an understand-
ing of their interaction could make the future for these 
fields bright. First, since none of the routes of MDM2-
targeting have shown satisfactory results in clinical tri-
als, the observation that PSMA siRNA can decrease 
MDM2 transcript levels [98] could provide another way 
of lessening MDM2 protein levels in tumor cells. This 
is an even more enticing idea when the expression of 
PSMA solely on tumor cells in most areas of the body 
is considered. Another therapeutic potential of this 
interaction could be the dual targeting of the proteins, 
to further lower MDM2 and PSMA levels in cells. 
Thus, further investigation of the interaction of these 
proteins is likely key to the improvement of MDM2- 
and PSMA-targeted therapeutics.
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